Heron Therapeutics (HRTX) reports strong growth in Q4 2025, driven by Acute Care franchise. Preliminary updates show net revenue of $40.5M for Q4, with ZYNRELEF at $12.5M, APONVIE at $3.8M, CINVANTI at $22.9M, and SUSTOL at $1.3M. FY25 net revenue totals $154.9M, with ZYNRELEF leading in quarter-over-quarter revenue increase. CEO Craig Collard expresses optimism for the company’s progress and performance. Source: TheFly.

Read more at Yahoo Finance: Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M